Richard Gordon leads the translational neuroscience program at The Queensland University of Technology Centre for Microbiome Research (CMR) within the Translational Research Institute (TRI) in Brisbane, Australia. His research program aims to understand how inflammatory pathways become activated and intestinal microbiota disrupted in Parkinson’s disease (PD), and how this contributes to disease progression. These findings are used to develop biomarkers for early diagnosis of PD as well as new treatment strategies aimed at slowing disease progression in people with PD. Dr. Gordon’s research has contributed to groundbreaking advances in this field, including most recently, the discovery of inflammasome activation as a driver of alpha-synuclein pathology and PD disease progression. Dr. Gordon is a certified toxicologist with the American Board of Toxicology (ABT) and serves on the Australian Therapeutics Goods Administration (TGA) Advisory Committee on Chemicals Scheduling. He is also a science ambassador for the World Parkinson Coalition (WPC).